Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
601-620 of 3,900 trials

Lower Respiratory Infections: Acyclovir Therapy

We are studying whether acyclovir can help ventilated patients with lower respiratory infections and herpes simplex virus. The trial aims to see if it improves survival and reduces hospital stays.

Pneumonia with Herpes Simplex Virus Infection6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

HER2-Positive Breast Cancer: GLSI-100 Treatment Study

We are testing a new peptide treatment for patients with HER2-positive breast cancer at high risk of recurrence after standard therapies. The study aims to see if it improves outcomes compared to a placebo.

Breast CancerHER2 Positive Breast Cancer>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteOncology

RA0127: First-in-Human Safety Study

We are testing a new drug, RA0127, in healthy young volunteers to see if it is safe and well-tolerated. This study will help us understand how the drug affects people before further testing.

Prevention of Gram-negative Bacterial InfectionsSafety phase (I)Infectious Diseases

Advanced Cancer: SOT201 Treatment Study

We are evaluating the safety and effectiveness of SOT201 in patients with advanced or metastatic cancer. This study aims to see how well this treatment works compared to current options.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Dupilumab for Young Children with Uncontrolled Asthma

We are studying whether dupilumab can help reduce severe asthma attacks in children aged 2 to under 6 years. The trial will also evaluate the safety and tolerability of this treatment.

Asthma and Wheezing1-2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteAllergologyPediatricsPulmonology

Heart Disease Treatment: Drug-Coated Balloon vs. Drug-Eluting Stents

We are comparing a new balloon treatment with standard stents for patients with heart disease at high risk of bleeding. The goal is to see if the new method is just as effective while requiring less blood-thinning medication.

Coronary Artery Disease>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Acetic Acid for Healing Skin Ulcers

We are studying whether acetic acid can help improve the healing of skin ulcers with biofilm compared to standard treatment. This trial will look at healing rates and safety over several weeks.

Skin Ulcer>2 yearsEfficacy phase (II)Standard MedicinesDermatology

Pulmonary Arterial Hypertension: Triple Therapy Study

We are investigating whether a new combination of treatments, including an injectable medication, improves health outcomes for patients with pulmonary arterial hypertension. This study compares it to a standard oral treatment to see which is more effective.

Pulmonary Arterial Hypertension6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Multiple Sclerosis: Frexalimab vs. Teriflunomide

We are studying a new medication, frexalimab, for adults with relapsing forms of multiple sclerosis. The goal is to see if it works better than teriflunomide in reducing relapses and improving quality of life.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Frexalimab for Nonrelapsing Secondary Progressive Multiple Sclerosis

We are studying whether frexalimab can help delay disability progression in adults with nonrelapsing secondary progressive multiple sclerosis. The trial also examines its effects on quality of life and safety.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Non-ST Elevation Acute Coronary Syndrome: Aspirin Omission Study

We are investigating if avoiding aspirin can reduce bleeding risks for patients with non-ST segment elevation acute coronary syndrome. The goal is to see if this approach is as effective as current treatments for heart issues.

Non-ST-Segment Elevation Acute Coronary Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Prostate Cancer: AMG 509 Treatment Study

We are testing a new drug called AMG 509 for men with metastatic castration-resistant prostate cancer. The study aims to evaluate its safety and how it may help manage this advanced stage of cancer.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Oncology

Advanced MTAP-null Solid Tumors: AMG 193 Treatment Study

We are studying the safety and effectiveness of AMG 193, both alone and with docetaxel, for adults with advanced MTAP-null solid tumors. This research aims to find better treatment options for these patients.

Advanced MTAP-null Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyHepatologyOncology

Cervical Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for women and young adults with high-risk locally advanced cervical cancer after initial treatment. This trial compares volrustomig to a placebo to see if it improves health outcomes.

Locally Advanced Cervical CancerConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteOncology

Retinitis Pigmentosa: New Treatment Trial

We are investigating a new treatment for patients with retinitis pigmentosa. The goal is to see if it can help improve vision or slow down vision loss.

Retinitis PigmentosaSafety phase (I)Efficacy phase (II)Ophthalmology

CMV Prevention in Lung Transplant Recipients: Letermovir Study

We are studying whether letermovir can better prevent CMV infection in lung transplant recipients compared to standard treatment with valganciclovir. This research may help improve care for patients at risk of CMV disease.

Lung Transplant Patients (D+/R-)1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Chronic Hepatitis D: Bulevirtide Treatment Study

We are studying the effects of Bulevirtide in patients with chronic hepatitis D to see how well it reduces the virus and improves liver health. This research will help us understand the treatment's safety and effectiveness over time.

Hepatitis DConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHepatologyInfectious Diseases

Traumatic Brain Injury: Wharton's Jelly Stem Cells

We are investigating whether stem cells from umbilical cord tissue can help reduce inflammation and improve immune response after a traumatic brain injury. This study aims to find new treatment options for recovery.

Severe Traumatic Brain Injury (TBI)>2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineNeurology

Secukinumab: Long-Term Safety Study

We are evaluating the long-term safety of Secukinumab for patients who have previously participated in a related study. This trial will help us understand any potential side effects of continued treatment.

Psoriatic ArthritisAnkylosing SpondylitisNon-radiographic Axial Spondyloarthritis>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyInternal MedicineRheumatology

Muscle Invasive Bladder Cancer: New Treatment Combination

We are studying a combination of three medications for patients with muscle invasive bladder cancer who cannot take cisplatin. The goal is to see if this approach can effectively shrink tumors before surgery.

Bladder CancerEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncologyUrology